20-HETE and blood pressure regulation: Clinical implications

Cardiology in Review

Volumn 22, Issue 1, 2014, Pages 1-12

  Wu, Cheng Chia ^a,b   Gupta, Tanush ^a   Garcia, Victor ^a   Ding, Yan ^a   Schwartzman, Michal L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b GREENWICH HOSPITAL   (United States)

Author keywords

20 HETE; androgen; angiotensin converting enzyme; CYP4A11; CYP4F2; hypertension

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ANDROGEN; CYTOCHROME P450 4A11; DIPEPTIDYL CARBOXYPEPTIDASE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; DNA POLYMORPHISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; GENE SEQUENCE; HUMAN; HYPERTENSION; KIDNEY TUBULE; LIPID METABOLISM; LIPOGENESIS; MICROVASCULATURE; NATRIURESIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; SODIUM ABSORPTION; VASCULITIS;

BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; KIDNEY TUBULES; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890560024     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3182961659     Document Type: Review

References (217)

1. Sacerdoti D, Escalante B, Abraham NG, et al. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science. 1989;243:388-390
2. Wu CC, Schwartzman ML. The role of 20-HETE in androgen-mediated hypertension. Prostaglandins Other Lipid Mediat. 2011;96:45-53
3. Ito O, Alonso-Galicia M, Hopp KA, et al. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol. 1998;274(2 pt 2):F395-F404
4. Ito O, Roman RJ. Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol. 1999;276(6 pt 2):R1749-R1757
5. Omata K, Abraham NG, Schwartzman ML. Renal cytochrome P-450- arachidonic acid metabolism: Localization and hormonal regulation in SHR. Am J Physiol. 1992;262(4 pt 2):F591-F599
6. Carroll MA, Sala A, Dunn CE, et al. Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. J Biol Chem. 1991;266:12306-12312
7. Escalante B, Erlij D, Falck JR, et al. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science. 1991;251:799-802
8. Ito O, Roman RJ. Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension. 1999;33(1 pt 2):419-423
9. Carroll MA, Kemp R, Cheng MK, et al. Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med Sci Monit. 2001;7:567-572
10. Croft KD, McGiff JC, Sanchez-Mendoza A, et al. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol. 2000;279:F544-F551
11. Imig JD, Zou AP, Stec DE, et al. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol. 1996;270(1 pt 2):R217-R227
12. Sun CW, Alonso-Galicia M, Taheri MR, et al. Nitric oxide-20- hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ Res. 1998;83:1069-1079
13. Kalsotra A, Strobel HW. Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism. Pharmacol Ther. 2006;112:589-611
14. Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol. 2008;75:2263-2275
15. Lasker JM, Chen WB, Wolf I, et al. Formation of 20- hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. JBiol Chem. 2000;275:4118-4126
16. Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation. 2005;111:63-69
17. Xu F, Falck JR, Ortiz de Montellano PR, et al. Catalytic activity and isoformspecific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther. 2004;308:887-895
18. Nguyen X, Wang MH, Reddy KM, et al. Kinetic profile of the rat CYP4A isoforms: Arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol. 1999;276(6 pt 2):R1691-R1700
19. Muller DN, Schmidt C, Barbosa-Sicard E, et al. Mouse Cyp4a isoforms: Enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J. 2007;403:109-118
20. Holla VR, Adas F, Imig JD, et al. Alterations in the regulation of androgensensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci U S A. 2001;98:5211-5216
21. Stec DE, Flasch A, Roman RJ, et al. Distribution of cytochrome P-450 4A and 4F isoforms along the nephron in mice. Am J Physiol Renal Physiol. 2003;284:F95-102
22. Parmentier JH, Lavrentyev EN, Falck JR, et al. Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells. Life Sci. 2005;77:1015-1029
23. Ito O, Nakamura Y, Tan L, et al. Expression of cytochrome P-450 4 enzymes in the kidney and liver: Regulation by PPAR and species-difference between rat and human. Mol Cell Biochem. 2006;284:141-148
24. Williams JM, Murphy S, Burke M, et al. 20-hydroxyeicosatetraeonic acid: A new target for the treatment of hypertension. J Cardiovasc Pharmacol. 2010;56:336-344
25. Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1-18
26. Heng YM, Kuo CS, Jones PS, et al. A novel murine P-450 gene, Cyp4a14, is part of a cluster of Cyp4a and Cyp4b, but not of CYP4F, genes in mouse and humans. Biochem J. 1997;325 (pt 3):741-749
27. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest. 2006;116:1696-1702
28. Helvig C, Dishman E, Capdevila JH. Molecular, enzymatic, and regulatory characterization of rat kidney cytochromes P450 4A2 and 4A3. Biochemistry. 1998;37:12546-12558
29. Marji JS, Wang MH, Laniado-Schwartzman M. Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries. Am J Physiol Renal Physiol. 2002;283:F60-F67
30. Muerhoff AS, Williams DE, Leithauser MT, et al. Regulation of the induction of a cytochrome P-450 prostaglandin omega-hydroxylase by pregnancy in rabbit lung. Proc Natl Acad Sci U S A. 1987;84:7911-7914
31. Capdevila JH, Karara A, Waxman DJ, et al. Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase. J Biol Chem. 1990;265:10865-10871
32. Singh H, Cheng J, Deng H, et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 2007;50:123-129
33. Bellamine A, Wang Y, Waterman MR, et al. Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch Biochem Biophys. 2003;409:221-227
34. Carroll MA, Balazy M, Huang DD, et al. Cytochrome P450-derived renal HETEs: Storage and release. Kidney Int. 1997;51:1696-1702
35. Minuz P, Jiang H, Fava C, et al. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 2008;51:1379-1385
36. Alonso-Galicia M, Falck JR, Reddy KM, et al. 20-HETE agonists and antagonists in the renal circulation. Am J Physiol. 1999;277(5 pt 2):F790-F796
37. Hercule HC, Oyekan AO. Cytochrome P450 omega/omega-1 hydroxylasederived eicosanoids contribute to endothelin(A) and endothelin(B) receptormediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther. 2000;292:1153-1160
38. Lee SJ, Landon CS, Nazian SJ, et al. Cytochrome P-450 metabolites in endothelin- stimulated cardiac hormone secretion. Am J Physiol Regul Integr Comp Physiol. 2004;286:R888-R893
39. Cambj-Sapunar L, Yu M, Harder DR, et al. Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke. 2003;34:1269-1275
40. Lin F, Rios A, Falck JR, et al. 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol. 1995;269(6 pt 2):F806-F816
41. Nakagawa K, Marji JS, Schwartzman ML, et al. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1055-R1062
42. Singh H, Schwartzman ML. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep. 2008;60:29-37
43. Alonso-Galicia M, Drummond HA, Reddy KK, et al. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension. 1997;29(1 pt 2):320-325
44. Alonso-Galicia M, Hudetz AG, Shen H, et al. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke. 1999;30:2727-2734; discussion 2734
45. López B, Moreno C, Salom MG, et al. Role of guanylyl cyclase and cytochrome P-450 on renal response to nitric oxide. Am J Physiol Renal Physiol. 2001;281:F420-F427
46. Oyekan AO, McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: Role of cytochrome p450-derived arachidonate metabolites. Br J Pharmacol. 1998;125:1065-1073
47. Botros FT, Laniado-Schwartzman M, Abraham NG. Regulation of cyclooxygenase- and cytochrome p450-derived eicosanoids by heme oxygenase in the rat kidney. Hypertension. 2002;39(2 pt 2):639-644
48. Coceani F, Kelsey L, Seidlitz E, et al. Inhibition of the contraction of the ductus arteriosus to oxygen by 1-Aminobenzotriazole, a mechanism-based inactivator of cytochrome P450. Br J Pharmacol. 1996;117:1586-1592
49. Hoagland KM, Maier KG, Roman RJ. Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl salt-sensitive rats. Hypertension. 2003;41(3 pt 2):697-702
50. Roman RJ, Ma YH, Frohlich B, et al. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension. 1993;21(6 pt 2):985-988
51. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31(1 pt 2):225-231
52. Vera T, Taylor M, Bohman Q, et al. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005;45:730-735
53. Zhou Y, Huang H, Chang HH, et al. Induction of renal 20- hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats. J Pharmacol Exp Ther. 2006;317:11-18
54. Zhou Y, Lin S, Chang HH, et al. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am J Hypertens. 2005;18(4 pt 1):530-537
55. Wang J, Roman RJ, Falck JR, et al. Effects of high-salt diet on CYP450-4A omega-hydroxylase expression and active tone in mesenteric resistance arteries. Am J Physiol Heart Circ Physiol. 2005;288:H1557-H1565
56. Wu JH, Hodgson JM, Clarke MW, et al. Inhibition of 20- hydroxyeicosatetraenoic acid synthesis using specific plant lignans: In vitro and human studies. Hypertension. 2009;54:1151-1158
57. Omata K, Tsutsumi E, Sheu HL, et al. Effect of aging on renal cytochrome P450-dependent arachidonic acid metabolism in Dahl rats. J Lipid Mediat. 1993;6:369-373
58. Kaduce TL, Fang X, Harmon SD, et al. 20-hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. J Biol Chem. 2004;279:2648-2656
59. Schwartzman ML, Falck JR, Yadagiri P, et al. Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J Biol Chem. 1989;264:11658-11662
60. Fang X, Dillon JS, Hu S, et al. 20-carboxy-Arachidonic acid is a dual activator of peroxisome proliferator-Activated receptors alpha and gamma. Prostaglandins Other Lipid Mediat. 2007;82:175-184
61. Hill E, Fitzpatrick F, Murphy RC. Biological activity and metabolism of 20-hydroxyeicosatetraenoic acid in the human platelet. Br J Pharmacol. 1992;106:267-274
62. Rosolowsky M, Falck JR, Campbell WB. Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omegaoxidized metabolites. Biochim Biophys Acta. 1996;1300:143-150
63. Cowart LA, Wei S, Hsu MH, et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator- Activated receptor ligands. J Biol Chem. 2002;277:35105-35112
64. Muller DN, Theuer J, Shagdarsuren E, et al. A peroxisome proliferator-Activated receptor-Alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol. 2004;164:521-532
65. Kroetz DL, Xu F. Regulation and inhibition of arachidonic acid omegahydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol. 2005;45:413-438
66. Su P, Kaushal KM, Kroetz DL. Inhibition of renal arachidonic acid omegahydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol. 1998;275(2 pt 2):R426-R438
67. Muerhoff AS, Williams DE, Reich NO, et al. Prostaglandin and fatty acid omega- and (omega-1)-oxidation in rabbit lung. Acetylenic fatty acid mechanism- based inactivators as specific inhibitors. J Biol Chem. 1989;264:749-756
68. Wang MH, Brand-Schieber E, Zand BA, et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: Characterization of selective inhibitors. J Pharmacol Exp Ther. 1998;284:966-973
69. Hacein-Bey L, Harder DR, Meier HT, et al. Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol. 2006;27:1350-1354
70. Seki T, Wang MH, Miyata N, et al. Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull. 2005;28:1651-1654
71. Miyata N, Taniguchi K, Seki T, et al. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol. 2001;133:325-329
72. Yu M, Cambj-Sapunar L, Kehl F, et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004;486:297-306
73. Tunctan B, Korkmaz B, Buharalioglu CK, et al. A 20- hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl] glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-Treated rats. Shock. 2008;30:329-335
74. Regner KR, Zuk A, Van Why SK, et al. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int. 2009;75:511-517
75. Laniado-Schwartzman M, Abraham NG. The renal cytochrome P-450 arachidonic acid system. Pediatr Nephrol. 1992;6:490-498
76. Lu M, Zhu Y, Balazy M, et al. Effect of angiotensin II on the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol. 1996;108:537-547
77. Nowicki S, Chen SL, Aizman O, et al. 20-Hydroxyeicosa-Tetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+- ATPase. J Clin Invest. 1997;99:1224-1230
78. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. JClin Invest. 1992;89:1496-1500
79. Ominato M, Satoh T, Katz AI. Regulation of Na-K-ATPase activity in the proximal tubule: Role of the protein kinase C pathway and of eicosanoids. J Membr Biol. 1996;152:235-243
80. Ribeiro CM, Dubay GR, Falck JR, et al. Parathyroid hormone inhibits Na(+)- K(+)-ATPase through a cytochrome P-450 pathway. Am J Physiol. 1994;266(3 pt 2):F497-F505
81. Silverstein DM, Barac-Nieto M, Falck JR, et al. 20-HETE mediates the effect of parathyroid hormone and protein kinase C on renal phosphate transport. Prostaglandins Leukot Essent Fatty Acids. 1998;58:209-213
82. Escalante BA, McGiff JC, Oyekan AO. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol Renal Physiol. 2002;282:F144-F150
83. Sánchez-Mendoza A, López-Sánchez P, Vázquez-Cruz B, et al. Angiotensin II modulates ion transport in rat proximal tubules through CYP metabolites. Biochem Biophys Res Commun. 2000;272:423-430
84. Escalante B, Erlij D, Falck JR, et al. Cytochrome P-450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb. Am J Physiol. 1994;266(6 pt 1):C1775-C1782
85. Wang W, Lu M. Effect of arachidonic acid on activity of the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol. 1995;106:727-743
86. Zou AP, Imig JD, Ortiz de Montellano PR, et al. Effect of P-450 omegahydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol. 1994;266(6 pt 2):F934-F941
87. Zhao X, Inscho EW, Bondlela M, et al. The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. Am J Physiol Heart Circ Physiol. 2001;281:H2089-H2096
88. Amlal H, LeGoff C, Vernimmen C, et al. ANG II controls Na(+)-K+(NH4+)- 2Cl- cotransport via 20-HETE and PKC in medullary thick ascending limb. Am J Physiol. 1998;274(4 pt 1):C1047-C1056
89. Grider JS, Falcone JC, Kilpatrick EL, et al. P450 arachidonate metabolites mediate bradykinin-dependent inhibition of NaCl transport in the rat thick ascending limb. Can J Physiol Pharmacol. 1997;75:91-96
90. Amlal H, Legoff C, Vernimmen C, et al. Na(+)-K+(NH4+)-2Cl- cotransport in medullary thick ascending limb: Control by PKA, PKC, and 20-HETE. Am J Physiol. 1996;271(2 pt 1):C455-C463
91. Wang W, Lu M, Balazy M, et al. Phospholipase A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL. Am J Physiol. 1997;273(3 pt 2):F421-F429
92. Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol. 1996;271(1 pt 1):C103-C111
93. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA. 1996;275:1581-1589
94. Roman RJ, Kaldunski M. Pressure natriuresis and cortical and papillary blood flow in inbred Dahl rats. Am J Physiol. 1991;261(3 pt 2):R595-R602
95. Roman RJ, Cowley AW Jr, Garcia-Estañ J, et al. Pressure-diuresis in volume- expanded rats. Cortical and medullary hemodynamics. Hypertension. 1988;12:168-176
96. Mattson DL, Lu S, Roman RJ, et al. Relationship between renal perfusion pressure and blood flow in different regions of the kidney. Am J Physiol. 1993;264(3 pt 2):R578-R583
97. Garcia-Estañ J, Roman RJ. Role of renal interstitial hydrostatic pressure in the pressure diuresis response. Am J Physiol. 1989;256(1 pt 2):F63-F70
98. Williams JM, Sarkis A, Lopez B, et al. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension. 2007;49:687-694
99. Granger JP. Pressure natriuresis. Role of renal interstitial hydrostatic pressure. Hypertension. 1992;19(1 suppl):I9-I17
100. Khraibi AA, Knox FG. Effect of renal decapsulation on renal interstitial hydrostatic pressure and natriuresis. Am J Physiol. 1989;257(1 pt 2):R44-R48
101. Khraibi AA, Haas JA, Knox FG. Effect of renal perfusion pressure on renal interstitial hydrostatic pressure in rats. Am J Physiol. 1989;256(1 pt 2):F165-F170
102. Haas JA, Granger JP, Knox FG. Effect of renal perfusion pressure on sodium reabsorption from proximal tubules of superficial and deep nephrons. Am J Physiol. 1986;250(3 pt 2):F425-F429
103. Kinoshita Y, Knox FG. Role of prostaglandins in proximal tubule sodium reabsorption: Response to elevated renal interstitial hydrostatic pressure. Circ Res. 1989;64:1013-1018
104. Roman RJ. Pressure-diuresis in volume-expanded rats. Tubular reabsorption in superficial and deep nephrons. Hypertension. 1988;12:177-183
105. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, et al. Inhibition of the formation of EETs and 20-HETE with 1-Aminobenzotriazole attenuates pressure natriuresis. Am J Physiol Regul Integr Comp Physiol. 2004;287:R58-R68
106. Zou AP, Drummond HA, Roman RJ. Role of 20-HETE in elevating loop chloride reabsorption in Dahl SS/Jr rats. Hypertension. 1996;27(3 pt 2):631-635
107. Stec DE, Mattson DL, Roman RJ. Inhibition of renal outer medullary 20-HETE production produces hypertension in Lewis rats. Hypertension. 1997;29(1 pt 2):315-319
108. Zhou Y, Luo P, Chang HH, et al. Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int. 2008;74:1040-1048
109. Stec DE, Deng AY, Rapp JP, et al. Cytochrome P4504A genotype cosegregates with hypertension in Dahl S rats. Hypertension. 1996;27(3 pt 2):564-568
110. Williams JM, Fan F, Murphy S, et al. Role of 20-HETE in the antihypertensive effect of transfer of chromosome 5 from Brown Norway to Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2012;302:R1209-R1218
111. Laffer CL, Laniado-Schwartzman M, Wang MH, et al. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension. Circulation. 2003;107:574-578
112. Laffer CL, Gainer JV, Waterman MR, et al. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension. 2008;51:767-772
113. Ward NC, Tsai IJ, Barden A, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008;51:1393-1398
114. Dahly AJ, Hoagland KM, Flasch AK, et al. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol. 2002;283:R757-R767
115. Williams JM, Sarkis A, Hoagland KM, et al. Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury. Am J Physiol Renal Physiol. 2008;295:F1764-F1777
116. Dahly-Vernon AJ, Sharma M, McCarthy ET, et al. Transforming growth factor- beta, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension. 2005;45:643-648
117. Harder DR, Gebremedhin D, Narayanan J, et al. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol. 1994;266(5 pt 2):H2098-H2107
118. Zhu D, Zhang C, Medhora M, et al. CYP4A mRNA, protein, and product in rat lungs: Novel localization in vascular endothelium. J Appl Physiol. 2002;93:330-337
119. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res. 2005;41:175-193
120. Amaral SL, Maier KG, Schippers DN, et al. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol. 2003;284:H1528-H1535
121. Jiang M, Mezentsev A, Kemp R, et al. Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res. 2004;94:167-174
122. Muthalif MM, Benter IF, Karzoun N, et al. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogenactivated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci U S A. 1998;95:12701-12706
123. Carroll MA, Balazy M, Margiotta P, et al. Cytochrome P-450-dependent HETEs: Profile of biological activity and stimulation by vasoactive peptides. Am J Physiol. 1996;271(4 pt 2):R863-R869
124. Oyekan A, Balazy M, McGiff JC. Renal oxygenases: Differential contribution to vasoconstriction induced by ET-1 and ANG II. Am J Physiol. 1997;273(1 pt 2):R293-R300
125. Oyekan AO, McGiff JC. Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am J Physiol. 1998;274(1 pt 2):R52-R61
126. Escalante B, Sessa WC, Falck JR, et al. Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J Pharmacol Exp Ther. 1989;248:229-232
127. Ma YH, Gebremedhin D, Schwartzman ML, et al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res. 1993;72:126-136
128. Inoue R, Jensen LJ, Jian Z, et al. Synergistic activation of vascular TRPC6 channel by receptor and mechanical stimulation via phospholipase C/diacylglycerol and phospholipase A2/omega-hydroxylase/20-HETE pathways. Circ Res. 2009;104:1399-1409
129. Randriamboavonjy V, Busse R, Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension. 2003;41(3 pt 2):801-806
130. Kaide J, Wang MH, Wang JS, et al. Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries. Am J Physiol Renal Physiol. 2003;284:F51-F56
131. Wang MH, Zhang F, Marji J, et al. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol Regul Integr Comp Physiol. 2001;280:R255-R261
132. Zhang F, Wang MH, Wang JS, et al. Transfection of CYP4A1 cDNA decreases diameter and increases responsiveness of gracilis muscle arterioles to constrictor stimuli. Am J Physiol Heart Circ Physiol. 2004;287:H1089-H1095
133. Zhang F, Wang MH, Krishna UM, et al. Modulation by 20-HETE of phenylephrine- induced mesenteric artery contraction in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 2001;38:1311-1315
134. Imig JD, Falck JR, Gebremedhin D, et al. Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. Hypertension. 1993;22:357-364
135. Inoue K, Sodhi K, Puri N, et al. Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am J Physiol Renal Physiol. 2009;297:F875-F884
136. Yaghini FA, Zhang C, Parmentier JH, et al. Contribution of arachidonic acid metabolites derived via cytochrome P4504A to angiotensin II-induced neointimal growth. Hypertension. 2005;45:1182-1187
137. Stec DE, Gannon KP, Beaird JS, et al. 20-Hydroxyeicosatetraenoic acid (20- HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem. 2007;19:121-128
138. Schulz E, Jansen T, Wenzel P, et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10:1115-1126
139. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol. 1990;30:535-560
140. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157
141. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res. 2000;87:840-844
142. Frisbee JC, Falck JR, Lombard JH. Contribution of cytochrome P-450 omegahydroxylase to altered arteriolar reactivity with high-salt diet and hypertension. Am J Physiol Heart Circ Physiol. 2000;278:H1517-H1526
143. Wang JS, Singh H, Zhang F, et al. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res. 2006;98:962-969
144. Sodhi K, Wu CC, Cheng J, et al. CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent. Hypertension. 2010;56:871-878
145. Wu CC, Cheng J, Zhang FF, et al. Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: Role of inhibitor of kappaB Kinase. Hypertension. 2011;57:788-794
146. Yu M, McAndrew RP, Al-Saghir R, et al. Nitric oxide contributes to 20-HETE-induced relaxation of pulmonary arteries. J Appl Physiol. 2002;93:1391-1399
147. Chen Y, Medhora M, Falck JR, et al. Mechanisms of activation of eNOS by 20-HETE and VEGF in bovine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;291:L378-L385
148. Cheng J, Ou JS, Singh H, et al. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol. 2008;294:H1018-H1026
149. Cheng J, Wu CC, Gotlinger KH, et al. 20-hydroxy-5,8,11,14- eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther. 2010;332:57-65
150. Ward NC, Chen K, Li C, et al. Chronic activation of AMP-Activated protein kinase prevents 20-hydroxyeicosatetraenoic acid-induced endothelial dysfunction. Clin Exp Pharmacol Physiol. 2011;38:328-333
151. Dunn KM, Renic M, Flasch AK, et al. Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2008;295:H2455-H2465
152. Izzard AS, Rizzoni D, Agabiti-Rosei E, et al. Small artery structure and hypertension: Adaptive changes and target organ damage. J Hypertens. 2005;23:247-250
153. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens. 2004;17(12 pt 1):1192-1200
154. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-Angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29:367-374
155. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003;108:1917-1923
156. Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation. 2003;108:2041-2048
157. Alom-Ruiz SP, Anilkumar N, Shah AM. Reactive oxygen species and endothelial activation. Antioxid Redox Signal. 2008;10:1089-1100
158. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97:730-737
159. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103:398-406
160. Ishizuka T, Cheng J, Singh H, et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 2008;324:103-110
161. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460
162. Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52:256-263
163. Csiszar A, Wang M, Lakatta EG, et al. Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. J Appl Physiol. 2008;105:1333-1341
164. Baeuerle PA. IkappaB-NF-kappaB structures: At the interface of inflammation control. Cell. 1998;95:729-731
165. Ungvari Z, Orosz Z, Labinskyy N, et al. Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am J Physiol Heart Circ Physiol. 2007;293:H37-H47
166. Sung B, Park S, Yu BP, et al. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: Suppression of NF-kappaB by 2,4-Thiazolidinedione. Exp Gerontol. 2006;41:590-599
167. Donato AJ, Eskurza I, Silver AE, et al. Direct evidence of endothelial oxidative stress with aging in humans: Relation to impaired endotheliumdependent dilation and upregulation of nuclear factor-kappaB. Circ Res. 2007;100:1659-1666
168. Chung HY, Sung B, Jung KJ, et al. The molecular inflammatory process in aging. Antioxid Redox Signal. 2006;8:572-581
169. de Winther MP, Kanters E, Kraal G, et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25:904-914
170. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin Sci (Lond). 2007;112:375-384
171. Theuer J, Dechend R, Muller DN, et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord. 2002;2:3
172. Henke N, Schmidt-Ullrich R, Dechend R, et al. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res. 2007;101:268-276
173. Guo AM, Arbab AS, Falck JR, et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20- hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther. 2007;321:18-27
174. Ward NC, Puddey IB, Hodgson JM, et al. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med. 2005;38:1032-1036
175. Guo AM, Scicli G, Sheng J, et al. 20-HETE can act as a nonhypoxic regulator of HIF-1alpha in human microvascular endothelial cells. Am J Physiol Heart Circ Physiol. 2009;297:H602-H613
176. Medhora M, Chen Y, Gruenloh S, et al. 20-HETE increases superoxide production and activates NAPDH oxidase in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;294:L902-L911
177. Le TH, Coffman TM. Targeting genes in the renin-Angiotensin system. Curr Opin Nephrol Hypertens. 2008;17:57-63
178. Cvetkovic B, Sigmund CD. Understanding hypertension through genetic manipulation in mice. Kidney Int. 2000;57:863-874
179. Alonso-Galicia M, Maier KG, Greene AS, et al. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2002;283:R60-R68
180. Tsai IJ, Croft KD, Puddey IB, et al. 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin- 1. Am J Physiol Heart Circ Physiol. 2011;300:H1194-H1200
181. Joly E, Seqqat R, Flamion B, et al. Increased renal vascular reactivity to ANG II after unilateral nephrectomy in the rat involves 20-HETE. Am J Physiol Regul Integr Comp Physiol. 2006;291:R977-R986
182. Xu F, Straub WO, Pak W, et al. Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol Regul Integr Comp Physiol. 2002;283:R710-R720
183. Chábová VC, Kramer HJ, Vanecková I, et al. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 2007;47:145-159
184. Muthalif MM, Karzoun NA, Gaber L, et al. Angiotensin II-induced hypertension: Contribution of Ras GTPase/Mitogen-Activated protein kinase and cytochrome P450 metabolites. Hypertension. 2000;36:604-609
185. Parmentier JH, Muthalif MM, Nishimoto AT, et al. 20- Hydroxyeicosatetraenoic acid mediates angiotensin ii-induced phospholipase d activation in vascular smooth muscle cells. Hypertension. 2001;37(2 pt 2):623-629
186. Cheng J, Garcia V, Ding Y, et al. Induction of angiotensin-converting enzyme and activation of the renin-Angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2012;32:1917-1924
187. Quigley R, Chakravarty S, Zhao X, et al. Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. Nephron Physiol. 2009;113:p23-p28
188. Fidelis P, Wilson L, Thomas K, et al. Renal function and vasomotor activity in mice lacking the Cyp4a14 gene. Exp Biol Med (Maywood). 2010;235:1365-1374
189. Wu CC, Mei S, Cheng J, et al: Androgen-sensitive hypertension is associated with upregulated vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol. 2013;24:1288-1296
190. Liu X, Zhao Y, Wang L, et al. Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney Int. 2009;75:1288-1296
191. Liu X, Wu J, Liu H, et al. Disturbed ratio of renal 20-HETE/EETs is involved in androgen-induced hypertension in cytochrome P450 4F2 transgenic mice. Gene. 2012;505:352-359
192. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010;125:446-463
193. Gainer JV, Lipkowitz MS, Yu C, et al AASK Study Group. Association of a CYP4A11 variant and blood pressure in black men. J Am Soc Nephrol. 2008;19:1606-1612
194. Fava C, Montagnana M, Almgren P, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373-380
195. Mayer B, Lieb W, Götz A, et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension. 2005;46:766-771
196. Williams JS, Hopkins PN, Jeunemaitre X, et al. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. J Hypertens. 2011;29:1913-1918
197. Fu Z, Nakayama T, Sato N, et al. A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men. J Hypertens. 2008;26:453-461
198. Lino Cardenas CL, Devos A, Toure A, et al. Arachidonic acid ω-hydroxylase CYP4A11: Inter-ethnic variations in the 8590T>C loss-of-function variant. Mol Biol Rep. 2012;39:1503-1508
199. Zhang R, Lu J, Hu C, et al. A common polymorphism of CYP4A11 is associated with blood pressure in a Chinese population. Hypertens Res. 2011;34:645-648
200. Sugimoto K, Akasaka H, Katsuya T, et al. A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population. Hypertension. 2008;52:1142-1148
201. Liu H, Zhao YY, Gong W, et al. [Correlation analysis and identification of G421C in regulatory region of CYP4F2 gene with essential hypertension]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006;28:143-147
202. Liu H, Zhao Y, Nie D, et al. Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol. 2008;19:714-721
203. .Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics. 2007;30:74-81
204. Munshi A, Sharma V, Kaul S, et al. Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol Biol Rep. 2012;39:1677-1682
205. Hu BC, Li Y, Li FH, et al. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese. J Hypertens. 2011;29:501-508
206. Fava C, Ricci M, Melander O, et al. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation? Prostaglandins Other Lipid Mediat. 2012;98:75-85
207. Fu Z, Nakayama T, Sato N, et al. Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects. Hypertens Res. 2008;31:1719-1726
208. Wiinberg N, Høegholm A, Christensen HR, et al. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens. 1995;8(10 pt 1):978-986
209. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208
210. Martins D, Nelson K, Pan D, et al. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: Data from NHANES II. J Gend Specif Med. 2001;4:10-3, 20
211. Ashton N, Balment RJ. Sexual dimorphism in renal function and hormonal status of New Zealand genetically hypertensive rats. Acta Endocrinol (Copenh). 1991;124:91-97
212. Chen YF, Meng QC. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci. 1991;48:85-96
213. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension. 1997;29(1 pt 2):494-499
214. Ouchi Y, Share L, Crofton JT, et al. Sex difference in the development of deoxycorticosterone- salt hypertension in the rat. Hypertension. 1987;9:172-177
215. Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: Role of the renin-Angiotensin system. Hypertension. 2000;35(1 pt 2):480-483
216. Reckelhoff JF, Zhang H, Srivastava K, et al. Gender differences in hypertension in spontaneously hypertensive rats: Role of androgens and androgen receptor. Hypertension. 1999;34(4 pt 2):920-923
217. Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31(1 pt 2):435-439